Table 1.
Japanese (JRSGC) [7] | Western: Goldstein et al. [4] | Padova [40] | Vienna [8] | Revised Vienna [9] | WHO [10] |
---|---|---|---|---|---|
Group I: Normal or benign | Reactive | Category 1: Negative for dysplasia | Category 1: Negative for dysplasia | Category 1: Negative for dysplasia | No intraepithelial neoplasia/dysplasia |
Group II: Benign with atypia | Indefinite for dysplasia | Category 2: Indefinite for dysplasia | Category 2: Indefinite for dysplasia | Category 2: Indefinite for dysplasia | Indefinite for intraepithelial neoplasia/dysplasia |
Group III: Borderline | Low-grade adenoma/dysplasia | Category 3.1: Noninvasive low-grade neoplasia (low-grade adenoma/dysplasia) | Category 3: Noninvasive low-grade neoplasia (low-grade adenoma/dysplasia) | Category 3: Mucosal low-grade neoplasia (low-grade adenoma/dysplasia) | Low-grade intrae pithelial neoplasia/dysplasia |
Group IV: Strongly suspicious for invasive carcinoma | High-grade adenoma/dysplasia | Category3.2: Noninvasive high-grade neoplasia (high-grade adenoma/dysplasia) | Category 4: Noninvasive high-grade neoplasia | Category 4: Mucosal high-grade neoplasia | High-grade intraepithelial neoplasia/dysplasia |
3.2.1: Suspicious for carcinoma (without lamina propria invasion) | 4.1: High-grade adenoma/dysplasia | 4.1: High-grade adenoma/dysplasia | |||
3.2.2: Noninvasive carcinoma (CIS) | 4.2: Noninvasive carcinoma (CIS) | 4.2: Noninvasive carcinoma (CIS) | |||
4.3: Suspicious ofinvasive carcinoma | 4.3: Suspicious for invasive carcinoma | ||||
4.4: Intramucosal carcinoma | |||||
Group V: Definitive for invasive carcinoma | Invasive carcinoma | Category 4: Suspicious for invasive carcinoma (with lamina propria invasion) | Category 5: Invasive neoplasia 5.1: Intramucosal carcinoma 5.2 Submucosal carcinoma or beyond | Category 5: Submucosal invasion by carcinoma | Intramucosal invasive neoplasia (intramucosal invasive carcinoma) |
Category 5: Invasive neoplasia (intramucosal/submucosal carcinoma or bevond) | Invasive neoplasia |
JRSGC, Japanese Research Society for Gastric Cancer; WHO, World Health Organization; CIS, carcinoma in situ.